Jupiter Neurosciences, Inc. (JUNS)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 1 | 1 | 0 | 0 | 0 | 0 | 0 | - |
| Operating profit | $m | -9 | -10 | ||||||
| Net profit | $m | -2 | -4 | -5 | -5 | -2 | -9 | -9 | - |
| EPS reported | $ | -18.75 | -19.33 | ||||||
| Operating cashflow per share | $ | -11.73 | -13.00 | ||||||
| Capex per share | $ | 0.00 | 0.00 | ||||||
| FCF per share | $ | -11.73 | -13.00 | ||||||
| Free cash flow | $m | -5 | -7 | ||||||
| Net debt | $m | 2 | 0 | ||||||
| Book value equity | $m | -2 | - | ||||||
| Book value per share | $ | -3.97 | -0.66 | ||||||
| Number of shares | m | 0.46 | 0.56 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | -19.28 | -7.98 | ||||||
| P/S LTM | x | 1,620.54 | 545.98 | ||||||
| P/FCF LTM | x | -6.52 | -4.87 | ||||||
| EV/EBITDA LTM | x | -4.30 | -3.88 | ||||||
| EV/Sales LTM | x | 1,690.73 | 42.77 | ||||||
| Earnings Yield LTM | % | -24.48% | -3.15% | ||||||
| FCF Yield | % | -15.33% | -20.52% | ||||||
| Quality | |||||||||
| ROE | % | +471.92% | +747.33% | ||||||
| ROIC | % | -2.55% | -7.09% | ||||||
| Operating margin | % | -408.73% | -151.67% | ||||||
| Gross margin | % | +80.59% | +88.34% | ||||||
| FCF/Sales | % | -24838.2% | -11206.0% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | - | - | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -1.02 | -4.14 | ||||||
| Net Debt/EBITDA | x | -0.18 | -0.02 | ||||||
| EBIT/Net interest | x | -134.94 | -382.35 | ||||||
| Net debt/market cap | % | +15.00% | +68.87% | ||||||
| Net debt/Equity | x | -0.82 | - | ||||||
| Gross debt/equity | x | -2.90 | - | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Jupiter Neurosciences, Inc. is a pharmaceutical company engaged in clinical-stage research and development. Its primary focus is on advancing a resveratrol-based platform product, with the main objective of addressing neuro-inflammation. The company's pipeline includes several drug candidates: JNS101 is undergoing Phase II trials for Friedreich's Ataxia, a rare neurological disorder that damages the nervous system and causes mobility issues. Also in Phase II, JNS102 is being developed for mucopolysaccharidosis Type I, JNS107 for MELAS Syndrome, and JNS108 for mild cognitive impairment and early Alzheimer's disease. Furthermore, the company is progressing JNS109 for amyotrophic lateral sclerosis, JNS110 for traumatic brain injury and concussion, and JNS120 as a treatment for COVID-19. Founded in 2016, the company, formerly known as Jupiter Orphan Therapeutics, Inc., adopted its current name in August 2021 and is headquartered in Jupiter, Florida.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Jupiter Neurosciences, Inc. (JUNS)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Jupiter Neurosciences, Inc. is a pharmaceutical company engaged in clinical-stage research and development. Its primary focus is on advancing a resveratrol-based platform product, with the main objective of addressing neuro-inflammation. The company's pipeline includes several drug candidates: JNS101 is undergoing Phase II trials for Friedreich's Ataxia, a rare neurological disorder that damages the nervous system and causes mobility issues. Also in Phase II, JNS102 is being developed for mucopolysaccharidosis Type I, JNS107 for MELAS Syndrome, and JNS108 for mild cognitive impairment and early Alzheimer's disease. Furthermore, the company is progressing JNS109 for amyotrophic lateral sclerosis, JNS110 for traumatic brain injury and concussion, and JNS120 as a treatment for COVID-19. Founded in 2016, the company, formerly known as Jupiter Orphan Therapeutics, Inc., adopted its current name in August 2021 and is headquartered in Jupiter, Florida.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free